J
Jacob Siegal
Guest
- Moderna's COVID-19 vaccine is 94.5% effective according to interim data from Phase 3 trials.
- 30,000 Americans participated in Moderna's vaccine study, and of the 95 people that tested positive for COVID-19, 90 of them had taken the placebo.
- Moderna's vaccine can be stored in a standard refrigerator for up to 30 days, and the company plans to ship up to 20 million doses in the US by the end of 2020.
Moderna announced in a press release on Monday morning that its coronavirus vaccine candidate is 94.5% effective in preventing infection with COVID-19. Moderna's Phase 3 study enrolled more than 30,000 participants in the United States, and the interim analysis of the data showed that of 95 confirmed COVID-19 cases among the participants, 90 received the placebo, while just five were injected with the mRNA-1273 vaccine.
Additionally, there was a secondary endpoint in which the company analyzed 11 severe cases among Phase 3 study participants. All eleven of these severe cases occurred among the placebo group, which means that, according to the company's earliest Phase 3 findings, no one who took the vaccine became severely ill.
Today's Best Deal
 | AccuMed Face Mask, Black (10 Count) $22.32 Available from Amazon Prime. BGR may receive a commission. Buy Now |
Continue reading...
Today's Top Deals
- Amazon’s week-long Black Friday 2020 sale is official – here are all the best deals
- Why pay $100+ for 3M N95 masks when these $2 FDA-authorized masks work even better?
- Get Lysol spray and wipes at Amazon before they’re sold out
Trending Right Now:
- New discovery may explain why certain coronavirus patients die
- There’s no explanation for this weird, glowing ball hovering over a forest in Mexico
- Walmart Black Friday ad: PS5 and Xbox Series X, plus cheap AirPods Pro
Moderna says its coronavirus vaccine is 94.5% effective so far originally appeared on BGR.com on Mon, 16 Nov 2020 at 09:00:36 EDT. Please see our terms for use of feeds.
Via BRG - Boy Genius Report